Ben-Levy R - Search Results

1

Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2.

Ben-Levy R, Leighton IA, Doza YN, Attwood P, Morrice N, Marshall CJ, Cohen P. Ben-Levy R, et al. EMBO J. 1995 Dec 1;14(23):5920-30. doi: 10.1002/j.1460-2075.1995.tb00280.x. EMBO J. 1995. PMID: 8846784 Free PMC article.

2

Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2.

Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ. Ben-Levy R, et al. Curr Biol. 1998 Sep 24;8(19):1049-57. doi: 10.1016/s0960-9822(98)70442-7. Curr Biol. 1998. PMID: 9768359 Free article. Review.

3

Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2.

Cano E, Doza YN, Ben-Levy R, Cohen P, Mahadevan LC. Cano E, et al. Among authors: ben levy r. Oncogene. 1996 Feb 15;12(4):805-12. Oncogene. 1996. PMID: 8632902

4

A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.

Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. Ben-Levy R, et al. EMBO J. 1994 Jul 15;13(14):3302-11. doi: 10.1002/j.1460-2075.1994.tb06632.x. EMBO J. 1994. PMID: 7913890 Free PMC article.

5

Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinases and c-Jun N-terminal kinases are activated by ischemia/reperfusion.

Bogoyevitch MA, Gillespie-Brown J, Ketterman AJ, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, Sugden PH. Bogoyevitch MA, et al. Among authors: ben levy r. Circ Res. 1996 Aug;79(2):162-73. doi: 10.1161/01.res.79.2.162. Circ Res. 1996. PMID: 8755992 Review.

6

Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3.

Zauberman A, Zipori D, Krupsky M, Ben-Levy R. Zauberman A, et al. Among authors: ben levy r. Oncogene. 1999 Jul 1;18(26):3886-93. doi: 10.1038/sj.onc.1202738. Oncogene. 1999. PMID: 10445852

7

Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.

Peles E, Ben-Levy R, Tzahar E, Liu N, Wen D, Yarden Y. Peles E, et al. Among authors: ben levy r. EMBO J. 1993 Mar;12(3):961-71. doi: 10.1002/j.1460-2075.1993.tb05737.x. EMBO J. 1993. PMID: 8096177 Free PMC article.

8

Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.

Peles E, Lamprecht R, Ben-Levy R, Tzahar E, Yarden Y. Peles E, et al. J Biol Chem. 1992 Jun 15;267(17):12266-74. J Biol Chem. 1992. PMID: 1351056 Free article.

9

An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.

Ben-Levy R, Peles E, Goldman-Michael R, Yarden Y. Ben-Levy R, et al. J Biol Chem. 1992 Aug 25;267(24):17304-13. J Biol Chem. 1992. PMID: 1355090 Free article.

10

Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.

Stancovski I, Peles E, Ben Levy R, Lemprecht R, Kelman Z, Goldman-Michael R, Hurwitz E, Bacus S, Sela M, Yarden Y. Stancovski I, et al. Among authors: ben levy r. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):95-103. doi: 10.1016/0960-0760(92)90192-l. J Steroid Biochem Mol Biol. 1992. PMID: 1356018 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page